ClinicalTrials.gg
Not yet recruitingNCT07748884Updated Aug 6, 2026

Comparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy

A Phase 4 interventional study of Fentanyl and Propofol and Esketamine and remimazolam in Adverse Respiratory Events, Hypoxemia and Children, sponsored by Second Affiliated Hospital of Wenzhou Medical University. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Second Affiliated Hospital of Wenzhou Medical University · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

Gastroscopy is important for diagnosing and treating upper gastrointestinal diseases in children. To ensure the procedure is safe and smooth, most children require sedation. Compared to adults, children have more fragile airways, lower lung capacity, and poorer oxygen reserves, making them more prone to breathing difficulties and low oxygen levels during sedation.

Esketamine, a stronger form of ketamine, helps maintain heart rate and blood pressure and may reduce breathing-related risks. Remimazolam, a new short-acting sedative, acts quickly, allows faster recovery, and has a better safety profile than propofol-it doesn't cause breathing problems or injection pain.

The safety and effectiveness of combining remimazolam with esketamine for pediatric gastroscopy have not been well studied. This research will compare this new combination with the traditional propofol-based approach to evaluate its potential benefits and safety in children.

Read the detailed description

Children scheduled for elective gastroscopy under general anesthesia were randomly allocated into two groups: the RA group (Remimazolam Besylate + Esketamine), consisting of 60 cases, and the PF group (Propofol + Fentanyl), also consisting of 60 cases. The induction doses for the RA group were: Remimazolam Besylate 0.65 mg/kg + Esketamine 0.5 mg/kg. The induction doses for the PF group were: Propofol 3 mg/kg + Fentanyl 2 μg/kg.

In the RA group, Esketamine 0.5 mg/kg was administered as a single intravenous bolus over 10 seconds. In the PF group, Fentanyl 2 μg/kg was administered as a single intravenous bolus over 10 seconds. After a 1-minute waiting period for both groups, Remimazolam Besylate 0.65 mg/kg was administered intravenously over 15 seconds in the RA group, while Propofol 3 mg/kg was administered intravenously over 15 seconds in the PF group. Gastroscopy commenced once the child's eyelash reflex disappeared and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score was ≤1.

The following parameters were recorded: the time from intravenous induction drug administration to loss of consciousness; the incidence of respiratory adverse events during anesthesia (defined as SpO₂ \<92% lasting ≥30 seconds, apnea, laryngospasm, or severe/persistent coughing); the success rate of intravenous anesthetic sedation; total gastroscopy procedure time; time to emergence from anesthesia; the incidence of postoperative agitation; MOAA/S scores; and vital signs including heart rate, blood pressure, and pulse oxygen saturation.

02

Conditions studied

  • Adverse Respiratory Events
  • Hypoxemia
  • Children
  • Gastroscopy
  • Esketamine
  • Remimazolam

Browse trials for

Keywords

  • Adverse respiratory events
  • Hypoxemia
  • Children
  • gastroscopy
  • Esketamine
  • Remimazolam
03

In context

Hypoxia

1,076 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

This study's planned enrollment of 120 is above the median of 45 across 769 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 137 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 6 to 12 years, both sexes;
  2. (ASA) physical status I or II;
  3. Scheduled for elective gastroscopy or esophagogastroduodenoscopy (EGD) under anesthesia;
  4. Preoperative oxygen saturation of 100% while breathing room air;
  5. Weight within the normal range for age and gender according to the following reference values (inclusive of endpoints)

Exclusion criteria

Exclusion Criteria:

  1. to sedation or anesthesia, or a history of adverse events related to sedation/anesthesia;
  2. Known or suspected allergy to the study drug, benzodiazepines, or their reversal agents;
  3. History of respiratory disease within the past 2 weeks, or known difficult airway (modified Mallampati score III or IV);
  4. History of cardiac, hepatic, renal dysfunction, or metabolic diseases;
  5. Patients with congenital diseases or other conditions that may interfere with the evaluation of efficacy outcomes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group PF

    Propofol 3 mg/kg + Fentanyl 2 μg/kg.

    Drug: Fentanyl and Propofol

  • Experimental
    Group RA

    Remimazolam Besylate 0.65 mg/kg + Esketamine 0.5 mg/kg.

    Drug: Esketamine and remimazolam

Interventions

  • DrugFentanyl and Propofol

    Drug pages: Fentanyl · Propofol

    In the PF group, Fentanyl 2 μg/kg was administered as a single intravenous bolus over 10 seconds. After a 1-minute waiting period for both groups, Propofol 3 mg/kg was administered intravenously over 15 seconds in the PF group.

  • DrugEsketamine and remimazolam

    Drug pages: Esketamine · Remimazolam

    In the RA group, Esketamine 0.5 mg/kg was administered as a single intravenous bolus over 10 seconds.After a 1-minute waiting period for both groups, Remimazolam Besylate 0.65 mg/kg was administered intravenously over 15 seconds in the RA group.

06

What researchers measure

Primary outcomes

  1. Respiratory Adverse Events During Anesthesia

    Respiratory adverse events are defined as the occurrence of any of the following during the anesthesia period: hypoxemia (SpO₂ \< 92% lasting ≥30 seconds), apnea, laryngospasm, and severe or persistent coughing.

    Time frame: From the start of anesthesia induction until the end of the procedure (gastroscopy withdrawal).

Secondary outcomes

  1. Success Rate of Intravenous Sedation

    Success is defined as achieving a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤ 1 with the initial dose of the study anesthetic agent.

    Time frame: Assessed at the time of anesthesia induction (immediately after initial dose administration).

  2. Success Rate of Gastroscopy Completion

    Successful gastroscopy must meet all three requirements: (1) procedure completed without need for alternative sedation; (2) no more than 3 rescue sedation boluses within 5 minutes; and (3) meeting the predefined limits for number and dose of rescue boluses.

    Time frame: From gastroscope insertion until its withdrawal (entire procedure duration).

  3. Emergence delirium

    The pediatric anesthesia emergence delirium scale consists of five items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score. pediatric anesthesia emergence delirium scale ≥12 at any time indicates presence of emergence delirium.

    Time frame: Within up to 15-30 minutes after child's first eye opening in the postoperative period

  4. Awakening time

    from the end of gastroscopy to first spontaneous eye-opening

    Time frame: From the withdrawal of the gastroscope (end of procedure) until the patient's first spontaneous eye-opening, assessed immediately during the post-anesthesia recovery period.

07

Study locations

1 site
  • The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou, Wenzhou, Zhejiang
    Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

Of 17 phase 4 interventional studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Aug 6, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07748884
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 6, 2026

Study contacts

Huacheng Liu, Ph.D.
Contact
huachengliu@163.com
13957770577 Ext. +86
Yuhang Cai, M.D.
Contact
838097626@qq.com
18815091585 Ext. +86
Huacheng Liu, Ph.D.
principal investigator · Second Affiliated Hospital of Wenzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fentanyl · Propofol · Esketamine · Remimazolam

Start the discussion